How can we increase the odds of successfully developing a medicine?
A study this week in the journal Nature says it goes all the way back to the initial experiments that are done on mice. If mouse studies were done more carefully, scientists would know more quickly which medicines would be successful for testing in humans.
Why does that matter? Getting it right in the beginning is critical because it means money and time would not be wasted on medicines that ultimately fail in clinical trials.
Improving the basics of early drug discovery is also the focus of the NIH Accelerated Medicine Program (AMP), which aims to identify the most promising biological targets for new therapies. We're participating in the AMP Alzheimer’s collaboration, where pharma companies will work together and share data to try to speed up the drug development process.